Psychedelic Clinical Trials
Find clinical trials studying psilocybin, MDMA, ketamine and other psychedelics. Many trials are actively recruiting participants who haven't found relief from conventional treatments.
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
Johns Hopkins University
Ketamine vs Lidocaine in Traumatic Rib Fractures
Brittany Hoyte
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Yale University
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
Bristol-Myers Squibb
Ketamine + Cognitive Training for Suicidality in the Medical Setting
Rebecca Price
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Sheppard Pratt Health System
Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder
Keith Heinzerling
Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia
Wilderman Medical Clinic
Opiate Suicide Study in Patients With Major Depression
Stanford University
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
University Hospital, Geneva
Perioperative Lidocaine and Ketamine in Abdominal Surgery
The Cleveland Clinic
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
Rennes University Hospital
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
Mayo Clinic
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Yale University
Facilitating Rapid Naltrexone Initiation
New York State Psychiatric Institute
Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain
Jason McMullan
Understanding How Ketamine Brings About Rapid Improvement in OCD
Stanford University
BMN 110 US Expanded Access Program
BioMarin Pharmaceutical
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
Janssen Research & Development, LLC
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
Mayo Clinic
Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
Neutrolis
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
MycoMedica Life Sciences PBC
Outcome of Multimodal Anesthesia Bern
Insel Gruppe AG, University Hospital Bern
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
The University of Texas Health Science Center at San Antonio
A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy
Novartis Pharmaceuticals
Dance Movement Therapy for Radio-oncological Patients
University of Erlangen-Nürnberg Medical School
Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants
University Hospital, Basel, Switzerland
Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures
Centre Hospitalier Universitaire de Nīmes
KF2024#1-trial: Esketamine Interaction Study
Helsinki University Central Hospital
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression
Centre Hospitalier Universitaire de Nīmes
A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
University of Washington
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression
Brian Barnett
A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies
Novartis Pharmaceuticals
Effect of Ketamine, Amitriptyline and Their Combination on Itch
Aalborg University
Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy
Tatiana Aboulafia Brakha
Low-Income Group Psilocybin Assisted Therapy for Depression
Matthew Hicks
Use of Ketamine in Severe Pain Syndromes
Erasme University Hospital
(GluEsk) Glutamate and Esketamine
University of Oxford
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)
University Hospital, Basel, Switzerland
Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients
Cessatech A/S
Opioid-based Versus Opioid-free Endotracheal Intubation
Aretaieion University Hospital
Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
Clexio Biosciences Ltd.
Comparison of Total Intravenous Anesthesia and Inhalational Anesthesia in Opioid-Free Anesthesia for Bariatric Surgery: A Randomized Controlled Trial
Jagiellonian University
LSD-Perceptual-Choice-Study
University Hospital, Basel, Switzerland
Psilocybin in Alcohol Use Disorder With Comorbid Depression
Centre Hospitalier Universitaire de Nīmes
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
University Hospital, Basel, Switzerland
Molecular Imaging Study of Harmine/DMT: a Basic Research Approach
Insel Gruppe AG, University Hospital Bern
Browse by Condition
View all conditions →How to Join a Clinical Trial
Clinical trials are research studies that test new treatments. Participating can give you access to cutting-edge therapies while contributing to medical science. Each trial has specific eligibility criteria based on the research goals.
1. Review
Read the trial details, eligibility criteria, and what participation involves.
2. Contact
Reach out to the study team using the contact information provided.
3. Screen
Complete the screening process to determine if you're eligible.